Neo Ivy Capital Management Takes $1.84 Million Position in Jazz Pharmaceuticals PLC $JAZZ

Neo Ivy Capital Management bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,930 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,836,000.

Other hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after buying an additional 298,815 shares during the period. LSV Asset Management increased its position in shares of Jazz Pharmaceuticals by 3.6% in the second quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock valued at $271,003,000 after acquiring an additional 87,576 shares during the period. Ameriprise Financial Inc. raised its stake in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after acquiring an additional 191,637 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Jazz Pharmaceuticals by 8.5% during the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after acquiring an additional 145,865 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter worth about $127,344,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 55,600 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the transaction, the executive vice president owned 56,862 shares of the company’s stock, valued at approximately $10,892,484.72. The trade was a 49.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the transaction, the senior vice president owned 28,728 shares in the company, valued at $5,587,308.72. This represents a 15.68% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 68,966 shares of company stock valued at $13,181,406. Company insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on JAZZ. Royal Bank Of Canada raised their target price on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Needham & Company LLC boosted their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Wells Fargo & Company boosted their price target on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. UBS Group reissued a “neutral” rating and issued a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Finally, Barclays began coverage on Jazz Pharmaceuticals in a research report on Friday, February 27th. They set an “overweight” rating and a $224.00 price objective on the stock. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $214.57.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $182.01 on Friday. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $198.00. The company has a market capitalization of $11.20 billion, a P/E ratio of -30.49, a price-to-earnings-growth ratio of 0.36 and a beta of 0.22. The firm has a 50 day moving average of $171.11 and a 200 day moving average of $153.84. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.49 by $0.15. The business had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The firm’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period in the prior year, the firm posted $6.51 EPS. As a group, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.